CAR-NK Cell Therapy: What It Is, Its Research Status, and the Cancer Care Acibadem Offers Instead

Important note: Acibadem hospitals do not offer CAR-NK (chimeric antigen receptor natural killer) cell therapy. CAR-NK therapy is investigational: at the time of writing it is not approved in any country and is available only within clinical trials. This page explains what CAR-NK therapy is and how it is being studied, so that patients and families can understand it, and then describes the established cancer treatments that Acibadem’s oncology and haematology teams do provide.

What CAR-NK Cell Therapy Is

Natural killer (NK) cells are white blood cells of the innate immune system. They can recognise and destroy some infected or abnormal cells without prior exposure to them, and they form part of the body’s natural defence against cancer.

In CAR-NK therapy, NK cells are modified in a laboratory to carry a chimeric antigen receptor (CAR), a synthetic receptor designed to bind to a particular protein on the surface of cancer cells. The aim is to direct the NK cells more precisely towards the tumour. The concept borrows from CAR-T cell therapy, which uses the same kind of receptor on T cells and is already approved for certain blood cancers.

Current Status: Investigational Only

At the time of writing, no CAR-NK product has regulatory approval anywhere in the world. CAR-NK therapy is given only to patients enrolled in clinical trials, most of which are early-phase studies designed to assess safety, suitable doses and first signs of activity in small groups of patients. These trials are run at a limited number of research centres.

Because the evidence is still early, it is not yet known how effective CAR-NK therapy is, for which cancers it may be useful, or how it compares with existing treatments. Claims that it is an established or widely available treatment are not supported by current evidence. Patients should confirm the status of any trial with their own oncologist and the relevant trial registry.

How CAR-NK Differs from CAR-T Therapy

CAR-T therapy normally uses the patient’s own T cells, which must be collected and engineered individually. NK cells behave differently from T cells, and researchers are investigating whether this brings practical advantages:

• Donor cells. NK cells may be less likely than T cells to attack the recipient’s healthy tissues, so many trials use cells from donors, umbilical cord blood, cell lines or stem cell sources. This could, in principle, allow cells to be prepared in advance rather than for each patient.
• Side effect profile. Researchers are studying whether CAR-NK cells cause less severe inflammatory and neurological side effects than CAR-T cells. Early reports are encouraging but come from small studies and are not conclusive.
• Persistence. NK cells generally survive for a shorter time in the body than CAR-T cells, which may limit how long any effect lasts. Several research approaches aim to address this.

Cancers Being Studied with CAR-NK Therapy

Most CAR-NK trials so far have involved blood cancers, such as certain lymphomas, leukaemias and multiple myeloma, often using targets similar to those of approved CAR-T products. Research in solid tumours is at an earlier stage, because solid tumours create an environment that suppresses immune cells and makes it harder for engineered cells to reach and act on the cancer. Inclusion in research does not mean that CAR-NK therapy is effective or available for a particular cancer.

How CAR-NK Treatment Is Given in Trials

Trial protocols vary, but the general process is similar to other cell therapies. After screening tests confirm that the patient meets the trial criteria, the patient usually receives a short course of lymphodepleting chemotherapy to make room for the infused cells. The CAR-NK cells are then given through a drip, sometimes in more than one dose. Patients are monitored closely in hospital and followed up with regular blood tests and scans according to the trial schedule.

Where donor-derived cells are used, there may be no need to collect the patient’s own cells beforehand, but this depends entirely on the design of the individual trial.

Possible Side Effects and Unknowns

Because CAR-NK therapy is experimental, its full safety profile is not yet known. Side effects reported or monitored for in trials include:

• low blood counts and infection, largely related to the preparatory chemotherapy;
• fever and infusion reactions;
• cytokine release syndrome and neurological effects, which are watched for as with other engineered cell therapies;
• unknown longer-term effects, which trials are designed to identify.

Taking part in a trial means accepting that benefits are uncertain. Trial teams are required to explain the known and potential risks before a patient gives consent.

Who May Be Considered for a CAR-NK Trial

Each trial sets its own eligibility criteria. These commonly include a specific cancer type that expresses the target protein, disease that has returned or not responded after standard treatment, adequate organ function and general fitness, and the ability to attend frequent follow-up visits at the trial centre. Many patients who ask about CAR-NK therapy will find that an approved treatment, including CAR-T therapy or a transplant for some blood cancers, is the more appropriate next step.

What Acibadem Offers Instead

Acibadem does not provide CAR-NK cell therapy, but its medical oncology teams, together with surgical, radiation oncology and haematology colleagues, provide the established treatments that remain the foundation of cancer care. Which of these applies depends on the type and stage of the cancer, previous treatment and the patient’s overall health:

• Tumour board review and second opinion. Pathology, imaging and treatment history are reviewed by a multidisciplinary group of oncologists, surgeons, radiation oncologists, radiologists and pathologists, who agree on a recommendation together. Where needed, pathology slides are re-examined and additional tests are performed.
• Immunotherapy. Immune checkpoint inhibitors are used where they are indicated for the specific cancer and stage.
• Targeted therapy. Medicines directed at specific molecular changes in the tumour, selected on the basis of biomarker testing.
• Chemotherapy, alone or combined with other treatments.
• Surgical oncology, including removal of the primary tumour and, in selected cases, of metastases.
• Radiation therapy, delivered by radiation oncology teams using modern planning techniques.
• For eligible blood cancers only: CAR-T cell therapy within its approved indications, and stem cell or bone marrow transplant, under the care of haematology teams. These treatments are not used for solid tumours outside approved indications.
• Blood cancer care. For lymphoma, leukaemia and multiple myeloma, haematology teams plan treatment according to the diagnosis, stage and previous therapy.

We can also review, together with the patient, whether a clinical trial elsewhere may be worth discussing with their own oncologist. We cannot promise referral to, or a place in, any trial; that decision rests with the trial team and its eligibility criteria.

Costs: What to Expect

Because CAR-NK therapy is investigational and Acibadem does not provide it, we do not quote prices for it. In clinical trials, the experimental treatment is usually provided under the trial’s own arrangements, while travel, accommodation and routine care may or may not be covered; patients should ask each trial team directly. For the treatments Acibadem does provide, our international patient team prepares a written, itemised estimate before travel.

Support for International Patients

Patients who travel to Acibadem for cancer assessment or treatment are supported by an international patient team that coordinates the transfer of medical records, pathology material and imaging, arranges appointments and hospital admission, and helps with visas, airport transfers and accommodation. Interpreters are available, and every patient receives a written treatment plan and a discharge report for their doctors at home. Patients who have read about CAR-NK therapy can use this pathway to obtain a second opinion on the treatments that are available to them now.

Next Steps

Patients and families who wish to have their situation reviewed can share recent reports, pathology results and imaging with our international patient team. An oncologist or haematologist will review which of the treatments available at Acibadem may be relevant and will explain honestly where they are not. This page is general information and does not replace an individual assessment by a specialist.

FAQ

Q: Does Acibadem offer CAR-NK cell therapy?

A: No. Acibadem hospitals do not offer CAR-NK cell therapy, which is investigational and available only in clinical trials. Our teams provide established cancer treatments and, for eligible blood cancers, CAR-T cell therapy and stem cell transplant within approved indications.

Q: What is CAR-NK cell therapy?

A: It is an experimental therapy in which natural killer cells are engineered to carry a chimeric antigen receptor that directs them towards a specific protein on cancer cells.

Q: Is CAR-NK therapy approved anywhere?

A: Not at the time of writing. No CAR-NK product has regulatory approval in any country, and the therapy is given only within clinical trials.

Q: How is CAR-NK different from CAR-T therapy?

A: CAR-T therapy uses engineered T cells, usually the patient’s own, and is approved for certain blood cancers. CAR-NK therapy uses engineered NK cells, often from donors or cell lines, and is still being studied for safety and effectiveness.

Q: Is CAR-NK therapy safer than CAR-T therapy?

A: Researchers are studying whether it causes fewer severe side effects, and some early reports are encouraging, but the studies are small and the question has not been answered.

Q: Which cancers is CAR-NK therapy being studied in?

A: Mainly blood cancers such as certain lymphomas, leukaemias and multiple myeloma, with earlier-stage research in solid tumours.

Q: What can Acibadem offer instead?

A: A multidisciplinary tumour board review and second opinion, and the established treatments that apply, such as immunotherapy with checkpoint inhibitors where indicated, targeted therapy, chemotherapy, surgery and radiotherapy, and, for eligible blood cancers, CAR-T cell therapy and stem cell or bone marrow transplant.

Q: Can Acibadem help with access to a CAR-NK clinical trial?

A: We can review, together with the patient, whether a clinical trial elsewhere may be worth discussing with their own oncologist. We cannot promise referral to or a place in any trial, as eligibility is decided by the trial team.

Q: How much does CAR-NK therapy cost?

A: Acibadem does not provide the therapy and does not quote prices for it. For the treatments Acibadem does provide, we give a written, itemised estimate before travel.